VAL: 3.60 -0.13 (▼3.33%)

Delayed:2018-02-16 16:57:10
Bid Price 3.50 High Price 3.85
Ask Price 3.75 Low Price 3.52
Open Price 3.66 Spread 6.90%
Prev Close 3.63 Volume 2,975,183.00

ValiRx Share Price Chart


Historic - 1 year

ValiRx Share Price Information

Name ValiRx Epic VAL
Sector Pharmaceuticals & Biotechnology ISIN GB00BWWYSP41
Activites ValiRx Plc is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in precision medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention. The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field. ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from Word class institutions, such as Cancer Research UK and Imperial College. Security Type Equity

Key numbers

Latest Share Price (p) 3.63 Net Gearing (%) 40.95
Market Cap (£m) 15.28 Gross Gearing (%) 52.26
Shares in issue (m) 407.46 Debt Ratio 0.00
P/E Ratio -0.44 Debt-to-Equity Ratio 0.00
Divs per share (p) 0.00 Assets / Equity Ratio 2.10
Dividend Yield (%) 0.00 Price to book value 6.45
Dividend Cover 0.00 SROCE (%) -242.62
Earning per share (p) -8.54 EPS Growth (%) -28.23
52-week high / low (p) 7.73 / 0.93 DPS Growth (%)

ValiRx Broker Views

Date Broker Rec. Price Old target price New target price Notes
12 Jan Beaufort Securities Speculative Buy 3.60 Reiterates
19 Dec Beaufort Securities Speculative Buy 3.60 Reiterates
16 Nov Beaufort Securities Speculative Buy 3.60 6.50 6.50 Reiterates
13 Oct Beaufort Securities Speculative Buy 3.60 6.50 6.50 Reiterates
29 Sep Beaufort Securities Speculative Buy 3.60 6.50 6.50 Reiterates

ValiRx Director Deals

ValiRx Company News

Valirx to present on 13 February 2018 at the Shares and AJ Bell Spotlight Evening in London

If you are looking for some new investment ideas for 2018, then come along the Shares and AJ Bell Investor Evening in London on Tuesday 13 February 2018. Directors from London Stock Exchange listed companies will present their latest plans regarding development and growth, you will have also have the opportunity to talk directly to the Directors and put forward your questions.

Valirx (VAL) - Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs.

Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers.

The Company's proprietary technology platform, GeneICE, enables selective silencing of rebellious genes' inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow.

Other companies presenting:

PrimaryBid - PrimaryBid the leading online equity funding platform, available on both web and mobile, that enables investors to gain access to placings, fundraisings and IPOs of AIM-listed companies. The platform is open to all investors and is supported by the broking community as a way of accessing, on behalf of their AIM clients seeking capital, the large and active private investor market, as well as institutions. To date almost £37m has been sourced for issuers, via the platform.

Rockhopper Exploration (RKH) - Rockhopper is an AIM listed oil and gas company based in the UK with interests in the Falkland Islands and the Greater Mediterranean region. Rockhopper's strategy is to build a well-funded, full-cycle, exploration led E&P company.

The Company is the leading acreage holder in the North Falkland Basin with independently audited 2C oil resources, net to Rockhopper, in excess of 250 mmbbl.

Through a series of acquisition and organic growth initiatives, Rockhopper has built a portfolio of production and exploration assets in the Greater Mediterranean which produced approximately 1,350 boepd during 2016 and is expected to generate material future exploration activity.

Sponsored by:

AJ Bell Youinvest


Shareholders and potential investors can register now for free at:

At 11:14am: (LON:VAL) ValiRx PLC share price was +0.25p at 4.5p

Story provided by

ValiRx welcomes positive clinical results

ValiRx has provided an update on the clinical progress of an anti-cancer compound developed by ValiSeek, a joint venture between ValiRx and Tangent Reprofiling.

Data analysed by Ariana, a digital health company, showed that the VAL401 treatment had a measureable improvement on patient quality of Life, in addition to a positive impact on the disease, ValiRx said.

At 8:27am: (LON:VAL) ValiRx PLC share price was +0.13p at 4.63p

Story provided by

ValiRx gets patent approval in the US

ValiRx, the clinical stage biotechnology company, has received patent approval in the US for its lead therapeutic compound, VAL201, which is in clinical trials.

The patent application covers the molecule and use of compounds in pharmaceutically acceptable products. The patent coverage also includes a wide variety of derivatives, modifications and analogues of the compounds and their mode of action.

Allowance of this US patent for VAL201 will represent one of the cornerstones of the company's commercial strategy, since ValiRx has already secured patent protection in several other territories, including Europe.

The compound is currently in a Phase I/II study primarily assessing safety and tolerability of VAL201 and its effect in the treatment of prostate cancer and other solid tumours.

So far VAL201 has met and exceeds the predicted safety and tolerability criteria set for the trial. Subjects have shown preliminary therapeutic efficacy and significant changes in their PSA levels related to treatment with VAL201. These are in line with pre-clinical studies, which have shown efficacy in prostate, breast and ovarian cancer models as well as addressing endometriosis or hormone induced abnormal cell growth in women.

Dr Satu Vainikka, CEO of ValiRx, said: "It is timely and very exciting to receive this notification of allowance for the VAL201 patent. This being only weeks after we received approval from the UK Medicines and Healthcare Products Regulatory Agency and Research Ethics Committee for the Company to expand its VAL201 trial to more speedily reach VAL201's full therapeutic potential and potential anti-cancer impact.

"This US allowance means we can proceed to strengthen the VAL201 patent portfolio and, once granted, will provide ValiRx with patent protection in all its largest commercial markets globally. ValiRx looks forward optimistically to its future prospects."

At 8:03am: (LON:VAL) ValiRx PLC share price was +0.95p at 5.8p

Story provided by

ValiRx releases encouraging test results

ValiRx said it had generated further positive results from tests of a lung cancer treatment.

Further to the release of pharmacokinetic data from the completed second-phase clinical trial, the company also released data pertaining to disease impact.

"The results demonstrate that the VAL401 treatment has a statistically significant improvement in overall survival for patients with non-small cell lung cancer compared to those receiving no treatment," the company said.

At 9:26am: (LON:VAL) ValiRx PLC share price was +1.13p at 4.25p

Story provided by

ValiRx obtains new US patent allowance

ValiRx said its joint venture with Tangent Reprofiling has obtained a new US patent allowance.

The clinical stage therapeutic compound VAL401 recently completed dosing in Phase II clinical trials to treat patients with lung cancer.

ValiSeek has received notification that a further method-of-treatment patent has been allowed covering the drug's use in the treatment of prostate adenocarcinoma.

International patents are pending across Europe, Asia, Australasia and in North and South America, providing coverage in all significant markets worldwide, ValiRx said.

"This allowance will further strengthen ValiSeek's portfolio at an important time in our development pathway and will grow the confidence of existing and potential partners, as far as bringing this compound closer to the marketplace," chief executive Suzy Dilly said.

At 8:06am: (LON:VAL) ValiRx PLC share price was +0.03p at 1p

Story provided by